Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial

- January 24th, 2018

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that the first patient in Cohort B has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD). As quoted in the press release: Dr Kilian Kelly, Cynata’s Vice President of Product Development, said “The … Continued

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that the first patient in Cohort B has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD).
As quoted in the press release:

Dr Kilian Kelly, Cynata’s Vice President of Product Development, said “The treatment of the first patient in Cohort B, and the ninth patient overall in this trial, is another milestone and value catalyst for the Company, bringing us closer to determining how safe and effective CYP-001 is in this devastating disease. In light of the very encouraging results from the initial cohort, and the higher dose level in Cohort B, we look forward to the final data with optimism.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply